Multiple drug resistance

Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”

Retrieved on: 
Thursday, August 10, 2023
Infection, Male, Multiple drug resistance, Human, Plantar fasciitis, Diabetes, S. aureus, Necrotizing fasciitis, Disclosure, MRSA, Recce, Type 2 diabetes, Therapeutic Goods Administration, Hope, ASX, FSE, Skin, Burn, Osteomyelitis, Confidentiality, Staphylococcus aureus, SAS, Stinger, Wound healing, Death, Patient, Length of stay, Swelling, Disease, Peripheral neuropathy, Fungal infection, Genetically modified bacteria, Mortality, TGA, Methicillin-resistant Staphylococcus aureus, Red, Gram-negative bacteria, Safety, RCE, Moyamoya disease, Pharmaceutical industry, Vaccine

“Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.

Key Points: 
  • “Antibiotic resistance is globally recognized as one of the greatest threats to human health today,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • “To see Recce making a difference for patients in such great medical need is a significant sign of new hope in the fight against drug-resistant superbugs.
  • Upon applying R327G, the initial redness and swelling had minimized after seven days, with the wound healing and drying up.
  • Surgical intervention was averted, such as limb amputation, which is common in patients with diabetes.

Spero Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Retrieved on: 
Thursday, July 29, 2021
Bacteria, Drug resistance, Multiple drug resistance, Tebipenem

ET to report its second quarter 2021 financial results and provide an update on its business and pipeline.

Key Points: 
  • ET to report its second quarter 2021 financial results and provide an update on its business and pipeline.
  • To access the call please dial 800-239-9838 (domestic) or 323-794-2551 (international) and refer to conference ID 1395205.
  • Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
  • In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

SCYNEXIS Announces Three Oral Presentations of Ibrexafungerp Demonstrating Clinical and In Vitro Activity Against Candida Species at the 31st ECCMID

Retrieved on: 
Monday, July 12, 2021
Antifungals, Branches of biology, Medical specialties, Infectious diseases, Yeasts, Pathogenic microbes, Echinocandins, Candida auris, Multiple drug resistance, Azole, Cándida, 1,3-Beta-glucan synthase

Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.

Key Points: 
  • Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids.
  • This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and intravenous (IV) formulations.
  • Ibrexafungerp is in late-stage development for multiple indications, including life-threatening fungal infections caused primarily by Candida (including C. auris) and Aspergillus species in hospitalized patients.
  • It has demonstrated broad-spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains.

Spero Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Bacteria, Drug resistance, Multiple drug resistance, Spero, Tebipenem

Details for the presentation are as follows:

Key Points: 
  • Details for the presentation are as follows:
    A webcast of the presentation may also be accessed through Spero Therapeutics website ( www.sperotherapeutics.com ) on the Events and Presentations page under the Investors and Media tab.
  • A replay of the presentation will be available on the website following the conclusion of the event.
  • Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
  • In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

China NMPA Approves MicuRx's Contezolid for Treatment of Drug-Resistant Bacterial Infection

Retrieved on: 
Thursday, June 3, 2021
2-Oxazolidone, Oxazolidinones, Multiple drug resistance, Infection, Health sciences, Medical specialties, Health care

Contezolid, designed and developed by MicuRx's China and US R&D team, is the next-generation oxazolidinone agent against multi-drug resistant (MDR) Gram-positive bacterial infection.

Key Points: 
  • Contezolid, designed and developed by MicuRx's China and US R&D team, is the next-generation oxazolidinone agent against multi-drug resistant (MDR) Gram-positive bacterial infection.
  • Contezolid isthe exciting productresulting fromthe company's 12 years' effort, which represents a major breakthrough forthe new drug discovery to combat infectious diseases in China.
  • MicuRx has successfully completed nine clinical trials of contezolid both in and outside of China.
  • MicuRx will launch contezolid first in China, which is expected to lead a new journey of novel anti-infective drugs in China.

Adaptive Phage Therapeutics Initiates Phase 1/2 Trial of PhageBank™ in Urinary Tract Infections

Retrieved on: 
Thursday, June 3, 2021
Health, Infectious diseases, Hospitals, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Bacteriophages, Life sciences, Health care, Phage therapy, Therapy, Bacteriophage, Multiple drug resistance, Pathogenic bacteria, Center for Innovative Phage Applications and Therapeutics, Robert T. Schooley

This multi-center clinical trial represents the first study of an expanding phage library for intravenous administration and/or bladder instillation of phage therapy.

Key Points: 
  • This multi-center clinical trial represents the first study of an expanding phage library for intravenous administration and/or bladder instillation of phage therapy.
  • PhageBank is APTs continually expanding phage library that functions as an integrated logistics platform to dispense phage on demand.
  • The PST enables rapid, automated identification of individual phage to be included in patient-specific therapy to treat bacterial infections.
  • Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

Spero Therapeutics to Participate at the Berenberg Conference USA

Retrieved on: 
Thursday, May 13, 2021
Health sciences, Articles, Health, Prodrugs, Tebipenem, Carbapenem, Multiple drug resistance, Antimicrobial resistance, Antibiotic

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat at the Berenberg Conference USA, taking place virtually from May 18 \xe2\x80\x93 20, 2021.
  • Details for the fireside chat are as follows:\nA webcast of the fireside chat may also be accessed through Spero Therapeutics\xe2\x80\x99 website ( www.sperotherapeutics.com ) on the \xe2\x80\x9cEvents and Presentations\xe2\x80\x9d page under the \xe2\x80\x9cInvestors and Media\xe2\x80\x9d tab.
  • A replay of the fireside chat will be archived on the website for 90 days following the conclusion of the event.\nSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.\nSpero\xe2\x80\x99s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).
  • In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.\nSpero is also developing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.\nSpero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.\n'

Adaptive Phage Therapeutics Announces $40.75 Million Series B Financing

Retrieved on: 
Tuesday, May 11, 2021
Professional services, Health, Infectious diseases, Finance, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Life sciences, Articles, Bacteriophage, Biology, Antimicrobial resistance, Drug resistance, Multiple drug resistance, Antibiotic, Pathogen, Therapy

b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.

Key Points: 
  • b'Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the company has closed a $40.75 million Series B investment round led by Deerfield Management Company.
  • Also joining the Series B round are existing investor Mayo Clinic and an additional undisclosed institutional investor.
  • Proceeds of this financing will be used to accelerate clinical development of PhageBank\xe2\x84\xa2 phage therapies, as well as for general corporate purposes.\nAPT\xe2\x80\x99s PhageBank\xe2\x84\xa2 technology is a growing collection of hundreds of bacteriophage, collectively providing broad spectrum coverage against six of the highest priority multi-drug resistant bacterial pathogens.
  • Together, we believe we can bring PhageBank\xe2\x84\xa2 therapy into the mainstream, and work to solve one of the key challenges facing modern medicine, the growing problem of antibiotic-resistant bacteria.\xe2\x80\x9d\nAdaptive Phage Therapeutics is a clinical-stage company advancing therapies to treat multi-drug resistant infections.

X-Biotix Therapeutics Announces Change in Corporate Strategy

Retrieved on: 
Monday, April 26, 2021
Health, Infectious diseases, Research, Pharmaceutical, Science, Biotechnology, Branches of biology, Health sciences, Medical specialties, Antibiotics, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Bacteriology, Antimicrobial resistance, Drug resistance, Bacteria, Multiple drug resistance

b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.

Key Points: 
  • b'X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of first-in-class antibiotic compounds targeting multi-drug-resistant Gram-negative pathogens, announced today a change in its strategy, which will include suspension of its current antibacterial research efforts.
  • Resistant infections cost the US $20B in excess healthcare costs and $35B in lost productivity.
  • Co-founders of the company include distinguished faculty from Harvard Medical School, with expertise in biological mechanisms of cell envelope biosynthesis, antibiotic resistance and efflux.
  • For further information, please visit: http://www.x-biotixrx.com/\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210426005029/en/\n'

ARCH Scientist Publishes Paper Showing Pre-Clinical Efficacy of AB569 in Eradicating Multi-Drug Resistant Pathogens Acinetobacter baumannii and Acinetobacter spp

Retrieved on: 
Thursday, March 4, 2021
Medical specialties, Moraxellaceae, Clinical medicine, Health care, Healthcare-associated infections, Acinetobacter, Drug resistance, Infection, Multiple drug resistance

Dr. Hassett, who collaborated with both the United States Air Force and Arch, demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumanniiand Acinetobacter spp.

Key Points: 
  • Dr. Hassett, who collaborated with both the United States Air Force and Arch, demonstrated that AB569 kills multi-drug resistant strains of Acinetobacter baumanniiand Acinetobacter spp.
  • These pathogens have been shown to infect soldiers who are injured by gun, shrapnel, burn or blast wounds.
  • For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com .
  • For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 [email protected]